AI Article Synopsis
- Thalidomide dosage in multiple myeloma treatment must be carefully managed due to its dose-dependent toxicity, which can lead to adverse events requiring dose adjustments or discontinuation.
- A study involving 93 newly diagnosed multiple myeloma patients evaluated the effects of a thalidomide dose step-up strategy, finding high overall response rates (78.5% overall, 98.7% in evaluable patients) and a median progression-free survival that was not reached.
- Common adverse events included constipation and skin rash, leading to dose reductions in about 22.6% of patients, highlighting the need for optimal supportive care alongside a step-up dosing strategy to ensure treatment efficacy and minimize intolerable side effects.
Article Abstract
Background: Thalidomide-containing regimens cause adverse events (AEs) that may require a reduction in treatment intensity or even treatment discontinuation in patients with multiple myeloma. As thalidomide toxicity is dose-dependent, identifying the most appropriate dose for each patient is essential.
Aims: This study aimed to investigate the effects of a thalidomide dose step-up strategy on treatment response and progression-free survival (PFS).
Methods And Results: This prospective observational study included 93 patients with newly diagnosed multiple myeloma (NDMM) who received bortezomib, thalidomide, and dexamethasone (VTD). The present study assessed the incidence of thalidomide dose reduction and discontinuation, the overall dose intensity, and their effects on therapeutic efficacy. Furthermore, this study used Cox proportional hazard models to analyze the factors contributing to thalidomide intolerability. The results showed the overall response rates in all patients and the evaluable patients were 78.5% and 98.7%, respectively. The median PFS in the study cohort was not reached. The most common thalidomide-related AEs were constipation (32.3%) and skin rash (23.7%), resulting in dose reduction and discontinuation rates of 22.6% and 21.5%, respectively. The responders had a significantly higher average thalidomide dose intensity than the nonresponders (88.6% vs. 42.9%, p < .001).
Conclusion: The thalidomide dose step-up approach is a viable option for patients with NDMM receiving VTD induction therapy with satisfactory efficacy and tolerability. However, thalidomide intolerance may lead to dose reduction or discontinuation due to unpredictable AEs, leading to lower dose intensity and potentially inferior treatment outcomes. In addition to a dose step-up strategy, optimal supportive care is critical for patients with multiple myeloma receiving VTD induction therapy.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11110097 | PMC |
| http://dx.doi.org/10.1002/cnr2.2102 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Tofacitinib in Leprosy: A Novel Therapeutic Approach in Chronic Recalcitrant Type II Reactions.
Cureus
November 2024
Dermatology, The Oxford Medical College, Hospital, and Research Centre, Bangalore, IND.
Leprosy is a chronic, infectious, and debilitating disorder that primarily affects the skin and peripheral nerves. The disease course may be complicated by immune-mediated reactions during or after therapy, which may further worsen nerve damage. Type II lepra reaction (T2LR) is a painful inflammatory condition with systemic features, such as fever, tender erythematous nodules, arthritis, neuritis, orchitis, lymphadenitis, and iritis.
View Article and Find Full Text PDFComparison of Efficacy and Safety Outcomes of Different Doses Schedules of Thalidomide for Treating Moderate-to-Severe β-Thalassemia Patients.
Ther Clin Risk Manag
November 2024
Department of Eugenics and Genetics, Guilin People's Hospital, Guilin, Guangxi Zhuang Autonomous Region, 541002, People's Republic of China.
Objective: In this study, we evaluated the effectiveness and safety of thalidomide by clinically observing 48 individuals with β-thalassemia who have been administered thalidomide in small and medium doses over a period of two years.
Methods: Thalidomide's efficacy was gauged by tracking hemoglobin (Hb) level alterations post its administration. Liver and kidney function impact was measured through tests for alanine aminotransferase, aspartate aminotransferase, blood urea nitrogen, and creatinine.
EFFECTIVENESS AND TOLERABILITY OF APREMILAST IN TREATMENT OF A SAMPLE OF PATIENTS WITH PSORIASIS.
Georgian Med News
September 2024
2Department of Pharmacology, College of Medicine, University of Baghdad, Iraq.
Aim: Current study was aimed to appraise the effectiveness and tolerability of apremilast in psoriasis patients at AL-Diwaniyah province, Iraq.
Materials And Methods: This prospective cross-sectional study conducted at Dermatology Unit/ AL-Diwaniyah Teaching Hospital/ Iraq, during the period from January to October 2023. A total of 125 patients, 90 males and 35 females, were enrolled in this study.
Therapeutic orphans, off-label, pediatric drug development: towards reasonable pharmacotherapy for minors.
Expert Opin Pharmacother
December 2024
Pediatric Neurology and Muscular Diseases Unit, Department of Neurosciences, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health, Giannina Gaslini Institute, University of Genova, Genova, Italy.
Introduction: The concept that children are therapeutic orphans emerged in the 1960s, triggering eventually worldwide legislation to facilitate pediatric studies, called 'Pediatric Drug Development (PDD).' However, PDD's true aim is not better medicines for children but labels in minors; minors are not another species.
Areas Covered: Absorption, distribution, metabolism, and excretion (ADME) differ in preterm newborns, but babies mature.
Dr. Raymond Alexanian: Pioneering Contributions to Multiple Myeloma Research, Treatment, and the Concept of Curability.
Clin Lymphoma Myeloma Leuk
September 2024
Department of Clinical Therapeutics, University of Athens, School of Medicine, Athens, Greece. Electronic address:
Article Synopsis
- Multiple myeloma is a complex type of blood cancer, and Dr. Raymond Alexanian has made significant contributions to its research and treatment over his nearly 50-year career.
- He developed the MP (melphalan-prednisone) regimen, which became a standard treatment, and collaborated with Dr. Bart Barlogie on the VAD (vincristine, doxorubicin, and dexamethasone) regimen to improve outcomes for difficult-to-treat cases.
- Dr. Alexanian also helped establish high-dose melphalan with autologous stem cell transplantation and evaluated new drugs like thalidomide and bortezomib, leaving a lasting impact on both patient care and the quest for a
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!